The occurrence of venous thromboembolism (VTE) in young women is a scenario frequently encountered in clinical practice. In this population, a VTE event is often associated with provoking risk factors such as use of hormones, pregnancy and postpartum period, inflammatory states, surgery or immobilization [1]. For the vast majority of these women the initial anticoagulant management strategy involves three months of therapeutically dosed anticoagulation [2]. After this initial treatment phase, for all patients, the decision has to be made to continue or discontinue anticoagulant therapy by shared decision and weighing the risk of recurrent VTE and the risk of anticoagulant related bleeding complications.
